Expedited Pathways Comparisons - US EU CHN
This presentation from Parexel's virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs" outlines regional comparisons of expedited pathways in US, EU and China.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021